Holen Sie sich die Stockscreener-App
2.90
4.69%
0.13
Marker Therapeutics Inc Aktie (MRKR) Neueste Nachrichten
Wedbush Securities Inc. Invests $393,000 in First Trust NASDAQ BuyWrite Income ETF (NASDAQ:FTQI) - Defense World
Biodesix, Inc. (NASDAQ:BDSX) Receives Average Recommendation of “Buy” from Analysts - Defense World
United Parks & Resorts Inc. (NYSE:PRKS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
Short Interest in Solventum Co. (NYSE:SOLV) Drops By 17.8% - Defense World
VanEck Pharmaceutical ETF (NASDAQ:PPH) Short Interest Down 17.3% in August - Defense World
MYR Group Inc. (NASDAQ:MYRG) Short Interest Update - Defense World
Phillips 66 (NYSE:PSX) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
Bank of New York Mellon Corp Acquires 36,810 Shares of SEI Investments (NASDAQ:SEIC) - Defense World
Raymond James & Associates Has $10.59 Million Stock Holdings in InvescoBulletShares2033 Corporate Bond ETF (NASDAQ:BSCX) - Defense World
MRKR Stock Earnings: Marker Therapeutics Beats EPS for Q2 2024 - MSN
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - StockTitan
Marker Therapeutics gets $2M NIH grant for MT-601 Phase 1 study - MSN
Marker Therapeutics Awarded $2 Million Grant from NIH in - GlobeNewswire
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma - StockTitan
Marker Therapeutics, Inc. Receives $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in Car-Relapsed Patients with Non-Hodgkin?s Lymphoma - Marketscreener.com
Breast Tissue Markers Market Size to be Worth USD 5.8 billion by 2034, Growing at CAGR of 8.3% | Exclusive Report by Transparency Market Research, Inc. - Yahoo Finance
NightHawk Changes Name To Scorpius Holdings - Contract Pharma
IDH Inhibitor Market to Exhibit Significant Growth Rate During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
IDH Inhibitor Market to Exhibit Significant Growth Rate During the Study Period (2020–2034) | DelveInsight - India Shorts
(MRKR) Investment Report - Stock Traders Daily
Soligenix (NASDAQ:SNGX) & Marker Therapeutics (NASDAQ:MRKR) Head-To-Head Contrast - Defense World
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $40.60 - Defense World
Financial Survey: EPR Properties (NYSE:EPR) and Bimini Capital Management (OTCMKTS:BMNM) - Defense World
Head to Head Comparison: Skye Bioscience (NASDAQ:SKYE) and Merck KGaA (OTCMKTS:MKGAF) - Defense World
Hematopoietic stem cell transplantation (HSCT) Market - openPR
Strong week for Marker Therapeutics (NASDAQ:MRKR) shareholders doesn't alleviate pain of five-year loss - Simply Wall St
Marker Therapeutics (NASDAQ:MRKR) Stock Price Up 5% - MarketBeat
Marker Therapeutics (NASDAQ:MRKR) Trading Up 5% - Defense World
Pliant Therapeutics Inc. (PLRX) Reports Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial - StreetInsider.com
(MRKR) Trading Report - Stock Traders Daily
BioZorb Lawuit- Breast Biopsy Marker Recall Lawyer - Levin Papantonio
MRKR Stock Earnings: Marker Therapeutics Reported Results for Q4 2023 - InvestorPlace
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors - Quantisnow
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs - GlobeNewswire
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs - ForexTV.com
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs - Yahoo Finance
Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment - Frontiers
Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results - Quantisnow
Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results - Quantisnow
Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML - Quantisnow
Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T ... - Quantisnow
Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility - Quantisnow
Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors - Quantisnow
Directors to Watch 2024: Gender Diversity - Directors and Boards
Hematopoietic stem cell transplantation (HSCT) Market Future Growth Trends, Upcoming Opportunities and ... - openPR
Directors to Watch 2024: Katharine Knobil - Directors and Boards
Coya Therapeutics reports ALS treatment stability at 6 months - Investing.com India
FDA Greenlights First Drug in Nearly a Decade for Rare Liver Disease - BioSpace
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology - Business Wire
A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis - Frontiers
J&J-backed Rapport Therapeutics valued at $636.8 mln in lukewarm debut - Reuters.com
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionAgenus (NASDAQ:AGEN), Barinthus Biothera - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionAgenus (NASDAQ:AGEN), Barinthus ... - Benzinga
Best Gene-Editing Stocks to Buy in 2024 - The Motley Fool
Panthera Resources (LON:PAT) Stock Price Down 5.5% - Defense World
Ambow Education (NYSEAMERICAN:AMBO) Trading 3.1% Higher - Defense World
American Stocks to Watch: Nvidia, Alibaba, GameStop, American Airlines, Robinhood - The Financial Express
Quarterly Metrics: Quick and Current Ratios for Marker Therapeutics Inc (MRKR) – DWinneX - The Dwinnex
Advancements and Applications in Hematopoietic Stem Cell Transplantation Market Is Likely to Experience a Huge ... - openPR
1.07%
2.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):